Concepedia

Pablo M. Bedano

PM

6

Publications

247

Citations

6

H-Index

2006

Active since

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Northern Indiana Cancer Research Consortium

Community Cancer Center

Pablo M. Bedano is an author at Indiana University – Purdue University Indianapolis specializing in cancer therapeutics, oncology, and medicine.

Top concepts

Publications per year

2006–2024

6

Publications

6

A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma

Pablo M. Bedano, SM Perkins, Matthew Burns et al. · Journal of Clinical Oncology · 2008 · 91 citations

, , +13

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors

Pablo M. Bedano, Mary J. Brames, Stephen D. Williams et al. · Journal of Clinical Oncology · 2006 · 54 citations · Full text

Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

Shadia I. Jalal, Pablo M. Bedano, Lawrence H. Einhorn et al. · Journal of Thoracic Oncology · 2010 · 51 citations · Full text

, , +8

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Timothy Lewis Cannon, Michael Rothe, Pam K. Mangat et al. · Journal of Clinical Oncology · 2024 · 20 citations

Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy

Pablo M. Bedano, M. Neubauer, Rafat Ansari et al. · Journal of Clinical Oncology · 2006 · 16 citations

, , +17

Rows per page

1–5 of 6